 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2025, vol. 31, issue1
Subject Area: Dental Medicine
-
DOI: 10.5272/jimab.2025311.6061
Published online: 10 March 2025
Original article
J of IMAB. 2025 Jan-Mar;31(1):6061-6068
RESEARCH ON RISK FACTORS FOR DEVELOPMENT OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS AMONG BULGARIAN PATIENTS OVER 18 YEARS OF AGE
Boryana Ilieva1
, Yanko G. Yankov2, 3, Tsvetelina Borisova-Papancheva4, Georgi Papanchev5, Vasil Sveshtarov1,
1) Department of Dental, Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Medical University of Sofia, Bulgaria.
2) Clinic of Maxillofacial Surgery, University Hospital "St. Marina", Varna, Bulgaria.
3) Department of General and Operative Surgery, Faculty of Medicine, Medical University Varna, Bulgaria.
4) Department of Conservative Dental Treatment and Oral Pathology, Faculty of Dental Medicine, Medical University of Varna, Bulgaria.
5) Department of Oral Surgery, Faculty of Dental Medicine, Medical University of Varna, Bulgaria.
ABSTRACT:
Introduction: The widespread use of bisphosphonates (BF) led to the discovery of a probable link with the subsequent development of osteonecrosis of the jaw. The aim of the present study is to investigate and analyze the risk factors for the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in the Bulgarian population and to compare with those described so far in the world literature.
Material and methodology: This is a retrospective study in which we included 44 patients with BRONJ treated and followed up by the authors' collective for 13 years (2009-2023). In all of them, demographic characteristics, primary disease, initiating cause of the necrosis, type of bisphosphonates, duration of BF therapy, mode of administration of BF, localization of the necrosis were observed and analysed.
Results: There was no statistically significant difference between the two sexes. BRONJ mainly affects patients in the age group of 61-70 years. A significantly higher proportion of the patients had a primary diagnosis of malignancy. The BF administered was mainly Zoledronic acid. BF was administered intravenously. In most of the patients dentoalveolar surgical intervention was carried out. The lower jaw, mainly the distal region, was affected.
Discussion: BRONJ is a multifactorial disease, and knowing the factors influencing the onset of the disease, as well as those influencing the outcome of its treatment, is of utmost importance when choosing a preventive and treatment strategy for the patients receiving BF.
Conclusions: The present article confirms that the demographic characteristics, etiology, and organ involvement of the Bulgarian population with BRONJ match the data in the world literature on the condition.
Keywords: bisphosphonates, osteonecrosis of the jaws, maxillofacial surgery, osteoporosis, malignant disease, tooth extraction, bisphosphonate intake, dentoalveolar surgical intervention,
- Download FULL TEXT /PDF 2061 KB/
Please cite this article as: Ilieva B, Yankov YG, Borisova-Papancheva T, Papanchev G, Sveshtarov V. Research on Risk Factors for Development of Bisphosphonate-Related Osteonecrosis of the Jaws Among Bulgarian Patients Over 18 Years of Age. J of IMAB. 2025 Jan-Mar;31(1):6061-6068. [Crossref - 10.5272/jimab.2025311.6061]
Correspondence to: Boryana Ilieva, Department of Dental, Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Medical University of Sofia; 1, St Georgi Sofiyski Blvd., 1431 Sofia, Bulgaria; E-mail: dr.ilieva@abv.bg
REFERENCES:
1. Scala R, Maqoud F, Antonacci M, Dibenedetto JR, Perrone MG, Scilimati A, et al. Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects. Front Pharmacol. 2022 Mar 15;13:837534. [PubMed]
2.Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. [PubMed]
3.Thomas JG, Ouanounou A. Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management. Front Oral Maxillofac Med. 2023 Dec 30;5:31. [Crossref]
4.Badros AZ, Meddeb M, Weikel D, Philip S, Milliron T, Lapidus R, et al. Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression. Front Oncol. 2021 Jun 24;11:704722. [PubMed]
5.Maciel AP, Quispe RA, Martins LJO, Caldas RJ, Santos PSDS. Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review. Sao Paulo Med J. 2020 Jul-Aug;138(4):326-35. [Crossref]
6.Kos M. Association of dental and periodontal status with bisphosphonate-related osteonecrosis of the jaws. A retrospective case controlled study. Arch Med Sci. 2014 Feb 24;10(1):117-23. [PubMed]
7.Boston B, Ipe D, Capitanescu B, Gresita A, Hamlet S, Love R, et al. Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients. J Am Geriatr Soc. 2023 Aug;71(8):2640-52. [Crossref]
8.Kos M, Luczak K, Godzinski J, Klempous J. Treatment of monostotic fibrous dysplasia with pamidronate. J Craniomaxillofac Surg. 2004 Feb;32(1):10-5.
9.Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011 Feb;1218:47-54. [PubMed ]
10.Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, Häuselmann H, et al. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis. J Bone Miner Res. 2022 Feb;37(2):340-8. [PubMed]
11.Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008 Sep;44(9):857-69. [PubMed]
12.Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012 Jun;40(4):303-9. [PubMed]
13.Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16;144(10):753-61. [PubMed]
14.Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75. [PubMed]
15.Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009 Nov 10;27(32):5356-62. [PubMed]
16.Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med. 2008 Jun;121(6):475-83. [PubMed]
17.Lesclous P, Grabar S, Abi Najm S, Carrel JP, Lombardi T, Saffar JL, et al. Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study. Clin Oral Investig. 2014 Mar;18(2):391-9. [Crossref]
18.Nakai F, Ohbayashi Y, Nakai Y, Iwasaki A, Miyake M. Bone metabolism of the jaw in response to bisphosphonate: a quantitative analysis of bone scintigraphy images. Odontology. 2020 Oct;108(4):653-60. [PubMed]
19.Dioguardi M, Di Cosola M, Copelli C, Cantore S, Quarta C, Nitsch G, et al. Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates. Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6359-73. [PubMed]
Received: 28 August 2024
Published online: 10 March 2025